Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes. (Q46017035)
Jump to navigation
Jump to search
scientific article published on 9 May 2009
Language | Label | Description | Also known as |
---|---|---|---|
English | Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes. |
scientific article published on 9 May 2009 |
Statements
1 reference
Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes. (English)
1 reference
Bruno Rotoli
1 reference
Carmine Selleri
1 reference
Bianca Serio
1 reference
Antonio M Risitano
1 reference
9 May 2009
1 reference
1 reference
88
1 reference
12
1 reference
1261-1262
1 reference
Identifiers
1 reference